drugset / Trial / NCT07796113
Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, exploratory clinical study enrolling patients with resectable, locally advanced thoracic esophageal squamous cell carcinoma (ESCC) confirmed by histology or cytology. The study aims to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab in combination with famitinib and chemotherapy in this population. The primary endpoint is the pathological complete response (pCR) rate, with a planned enrollment of 24 patients.
Timeline
- Start
- 2025-10-30
- Primary completion
- 2028-10-30
- Completion
- 2028-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Famitinib | Small molecule | 10 mg | Oral |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |